Categories
Business Express

SPARC slips 10% as USFDA rejects cancer drug application

Enterprise Regular

The business has received a Total Reaction Letter (CRL) from the USFDA for the new drug software (NDA) for Taclantis (Paclitaxel Injection Focus for Suspension).


SI Reporter  | 
Mumbai 




medicine, drug, drugs, tablets

Image: Shutterstock

Shares of Sun Pharma Sophisticated Research Organization (SPARC) slipped ten for each cent to Rs 172 on the BSE on Wednesday in an usually strong current market following the US wellbeing regulator rejected the cancer drug software.

SPARC on Tuesday explained the business has received a Total Reaction Letter (CRL) from the United States Foodstuff & Drug Administration (USFDA)

Read More